1-3 of 3
Sheila J. O’Connor, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Hazem A. Sayala, MD, Paul Moreton, MD, Richard A. Jones, PhD, Andy C. Rawstron, PhD, Sheila J. O’Connor, PhD, Paul Evans, PhD, Carter Anthony, MsC, Claire Dearden, MD, Estella Matutes, MD, PhD, Andrew R. Pettitt, MD, PhD, Daniel B. Kennedy, MD, Peter Hillmen, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 34.
https://doi.org/10.1182/blood.V108.11.34.34
Published: 2006
Journal Articles

EBV Related Transformation Events in CLL.

Hazem A. Sayala, MD, Sheila J. O’Connor, PhD, Andrew S. Jack, PhD, Chetan Patalappa, Peter Hillmen, MD, PhD, Roger G. Owen, MD
Journal: Blood
Blood (2006) 108 (11): 4963.
https://doi.org/10.1182/blood.V108.11.4963.4963
Published: 2006
Journal Articles

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

Sheila J. O’Connor, PhD, Kathryn Turner, MSc, Sharon L. Barrans, PhD, Brad Dickinson, MSc, Andy C. Rawstron, PhD, Hazem Sayala, MD, Paul Moreton, MD, Roger G. Owen, MD, Andrew S. Jack, PhD, Peter Hillmen, PhD
Journal: Blood
Blood (2005) 106 (11): 2936.
https://doi.org/10.1182/blood.V106.11.2936.2936
Published: 2005